SESSION TITLE: Student/Resident Case Report Poster - Pulmonary Vascular Disease II
SESSION TYPE: Student/Resident Case Report Poster
PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM
INTRODUCTION: Pulmonary hypertension (PH) in association with neurofibromatosis is relegated to group 5 diagnostic group by the 5th World Symposium on PH. Currently, there are no FDA-approved treatments for group 5 PH. Nonetheless, the PH is due to elevated pulmonary vascular resistance (PVR) and may respond to pulmonary vasodilator therapy.